With all the time and attention surrounding the BCMA-based products in multiple myeloma, including ADCs and CAR-T cell therapies, it’s easy to forget there are other approaches coming down the pike.
Building new mosaics and novel regimens in myeloma is coming
Beyond the hullabaloo there are various bispecific antibodies and T cell engagers in early stage development – not only is the modality different, but the targets might differ too.
How are all of these novel approaches doing in the clinic and how might they all fit together in future regimens? The myeloma world as we know it of proteasome inhibitors and IMiDs may not yet be a thing of the past, but the landscape is certainly changing.
In our third installment of the myeloma mini-series, we tackle these issues and look at near and medium term strategic directions, which can be considered and how these might impact different combination approaches and lines of therapy in order to further improve outcomes in this disease.
To learn more from our oncology analysis and get a heads up on the latest insights and analysis pertaining to the multiple myeloma landscape, subscribers can log-in or you can click to gain access to BSB Premium Content.
After a totally crazy last week, I must say it’s a tremendous relief to get back to focusing on science and early stage clinical development!
Behind the all the ongoing political and Covid-19 furore, the ASH abstracts dropped unexpectedly early on November 4th instead of Bonfire Night and this week it’s the start of the SITC meeting with live presentations already starting.
Every year we post a series of Previews highlighting key data to watch out for on key selected topics. The focus varies with each meeting with a look at different targets, modalities, or tumour types. This year we’re kicking off our coverage with a focused look at bispecific antibodies in early development…
Are bispecifics flying high at ASH20?
To learn more from our oncology analysis and get a heads up on the latest insights and commentary pertaining to the ASH meeting — including our first meeting Preview of 2020, subscribers can log-in or you can click to gain access to BSB Premium Content.
Virtual meetings mean we miss the fun of German pop-up sausage stands and focus solely on the new emerging clinical data!
EHA25 Virtual, Not-In-Frankfurt – There’s a lot of commercial interest in CD20 x CD3 bispecifics, and in this post we’re taking a look at some of the latest clinical data presented at recent ASCO and EHA virtual meetings. Companies mentioned include Regeneron, Roche/Genentech, Genmab/Abbvie, Xencor, and IGM Biosciences.
Any analysis of a rapidly evolving and fast-moving landscape only represents a snapshot in time at the point it was taken, and this post is not intended to be a comprehensive landscape report, you’d pay a lot more than a yearly sub to BSB for that, but we’ve been following the field, and there are some trends emerging.
What makes it interesting is there is some nuance required in the interpretation of data, and with that in mind we spoke to an investigator at the forefront of clinical research who has done trials with several of the CD20 x CD3 bispecifics in development; the insights were quite illuminating.
This post offers an update on the CD20 bispecific landscape, analysis of some of the recent data at EHA and ASCO, as well as expert opinion, what more could you ask for?
To read our latest expert interview, and gain insights from our oncology analysis and commentary around data emerging from the ASCO and EHA virtual meetings, subscribers can log-in or you can click to gain access to BSB Premium Content.
Continuing our ASCO20 coverage with another Preview in the pre-meeting series, we turn our attention to a particular modality of keen interest to many of our readers.
In this latest article, we highlight ten areas within the niche and include an array of companies, both big and small, across Pharma and Biotechs.
Some of them have some nice data to share, others will be footnotes to the meeting, but who fits into what category and what can we learn from the abstracts upfront?
To find out more, we looked very carefully at the hints and nuance which inevitably grace the writer’s pen – it’s time to hone in on where are the flourishes and the crossings out this year?
To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the ASCO meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.
Downtown San Francisco
San Francisco — Amongst all the chaos and frenetic activity that abounds big Pharma at JPM each year, I always look forward to hearing what the smaller biotechs are up to on days 3 and 4, as well as seeing how far some of them have progressed since our previous update on their pipeline agents.
In this latest update, there are definitely some companies we have been following longitudinally who are either poised for future success and growth… or due for a correction if the promising science doesn’t pan out as expected in the clinic.
Indeed one of those companies has already hit success and disappointment in the last two months alone, such is the roller coaster that is oncology R&D.
Please note that this is a rolling blog, which means that numerous updates are added throughout the day as new information becomes available.
To learn more from our oncology coverage and get a heads up on our latest commentary JPM annual meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.
Bispecifics in the garden? Who knows!
We’re continuing our preview of the ASCO 2019 annual meeting (Twitter #ASCO19) with a look at a fast-paced area of drug development that is attracting a lot of interest, namely the potential of bispecifics as novel cancer treatments.
On BSB we’ve been following this emerging field for the past five years or so, but at this year’s ASCO we expect to hear clinical data that may offer new insights.
If you’ve been in London this past week, then you may have been at the annual Royal Horticultural Society (RHS) Chelsea Flower Show, which features impressively designed show gardens built around a theme or location. They’re built with great attention to detail just for Chelsea, then at a few days they’re dismantled.
Large cancer meetings like ASCO19 are a bit like that too. We all come together for a few days to mix and mingle then go our separate ways again.
In the spirt of Chelsea, in this post we’re taking a look at what to watch for in the “ASCO19 bispecific garden,” if one were to be made. There’s certainly a surfeit of choice to consider and like flowers, some may flourish under certain conditions, but not others.
To learn more from our latest conference coverage and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.